Glucagon

Modify Date: 2024-01-09 20:50:28

Glucagon structure	Common Name	Glucagon
	CAS Number	9007-92-5	Molecular Weight	3519.21000
	Density	N/A	Boiling Point	230ºC at 760 mm Hg
	Molecular Formula	C₁₅₃H₂₂₆ClN₄₃O₄₉S	Melting Point	-15ºC
	MSDS	N/A	Flash Point	N/A

Use of Glucagon

Glucagon exhibits marked effects on protein and amino acid metabolism. Glucagon inhibits the incorporation of amino acids into protein of liver, muscle, and pancreas, to increase excretion of nitrogen, to promote hepatic urea synthesis, and to increase the concentration of hepatic transaminases and urea cycle enzymes. Glucagon can promote the hepatic uptake of amino acids, to enhance their incorporation into liver glycogen, and to depress the concentration of amino acids in blood[1].

Name	glucagon hydrochloride(human)
Synonym	More Synonyms

Description	Glucagon exhibits marked effects on protein and amino acid metabolism. Glucagon inhibits the incorporation of amino acids into protein of liver, muscle, and pancreas, to increase excretion of nitrogen, to promote hepatic urea synthesis, and to increase the concentration of hepatic transaminases and urea cycle enzymes. Glucagon can promote the hepatic uptake of amino acids, to enhance their incorporation into liver glycogen, and to depress the concentration of amino acids in blood[1].
Related Catalog	Signaling Pathways >> Others >> Others Research Areas >> Metabolic Disease
References	[1]. Bromer WW, Chance RE. Zinc glucagon depression of blood amino acids in rabbits. Diabetes. 1969 Nov;18(11):748-54.

Boiling Point	230ºC at 760 mm Hg
Melting Point	-15ºC
Molecular Formula	C₁₅₃H₂₂₆ClN₄₃O₄₉S
Molecular Weight	3519.21000
Exact Mass	3516.59000
PSA	1564.04000
LogP	0.39110
Appearance of Characters	powder
Storage condition	2-8°C

CHEMICAL IDENTIFICATION

RTECS NUMBER :: LZ3980000

CHEMICAL NAME :: Glucagon

CAS REGISTRY NUMBER :: 9007-92-5

LAST UPDATED :: 199704

DATA ITEMS CITED :: 15

MOLECULAR FORMULA :: C151-H224-N42-O50-S

MOLECULAR WEIGHT :: 3460.23

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >200 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 200 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 100 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >200 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >200 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >200 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 200 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >200 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: >10 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 140 mg/kg/4W-I

TOXIC EFFECTS :: Liver - changes in liver weight Endocrine - hyperglycemia Blood - changes in erythrocyte (RBC) count

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 140 mg/kg/4W-I

TOXIC EFFECTS :: Liver - changes in liver weight

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 3600 ug/kg

SEX/DURATION :: female 16-21 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

MUTATION DATA

TYPE OF TEST :: Unscheduled DNA synthesis

TEST SYSTEM :: Rodent - rat Liver

DOSE/DURATION :: 75 mg/L

REFERENCE :: EJBCAI European Journal of Biochemistry. (Springer-Verlag New York, Inc., Service Center, 44 Hartz Way, Secaucus, NJ 07094) V.1- 1967- Volume(issue)/page/year: 34,474,1973 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - 83978 No. of Facilities: 33 (estimated) No. of Industries: 1 No. of Occupations: 4 No. of Employees: 825 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - 83978 No. of Facilities: 109 (estimated) No. of Industries: 1 No. of Occupations: 5 No. of Employees: 11153 (estimated) No. of Female Employees: 9781 (estimated)

Safety Phrases	22-24/25
RIDADR	NONH for all modes of transport
WGK Germany	3
RTECS	LZ3980000

Over-expression of Follistatin-like 3 attenuates fat accumulation and improves insulin sensitivity in mice.

Metab. Clin. Exp. 64(2) , 283-95, (2015)

Follistatin-like 3 (fstl3), a natural inhibitor of members of the TGF-β family, increases during resistance training in human plasma. Fstl3 primarily binds myostatin and activin A, and thereby inhibit...

Comparison of the effects of slowly and rapidly absorbed carbohydrates on postprandial glucose metabolism in type 2 diabetes mellitus patients: a randomized trial.

Am. J. Clin. Nutr. 100(4) , 1059-68, (2014)

Isomaltulose attenuates postprandial glucose and insulin concentrations compared with sucrose in patients with type 2 diabetes mellitus (T2DM). However, the mechanism by which isomaltulose limits post...

Glucagon secretion after metabolic surgery in diabetic rodents.

J. Endocrinol. 223(3) , 255-65, (2014)

Excessive or inadequate glucagon secretion promoting hepatic gluconeogenesis and glycogenolysis is believed to contribute to hyperglycemia in patients with type 2 diabetes. Currently, metabolic surger...

Glucagon hydrochloride

Glucagonoid

Hyperglycemic-glycogenolytic factor

glukagonnovo

Glucagon RecoMbinant

l-histidyl-l-seryl-l-glutaminylglycyl-l-threonyl-l-phenylalanyl-l-l-threonin

Glukagon

MFCD00167532

HG-Factor

Glucagon

Use of Glucagon

Names

Glucagon Biological Activity

Chemical & Physical Properties

Toxicological Information

CHEMICAL IDENTIFICATION

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

MUTATION DATA

Safety Information

Articles88

Synonyms